FEV1 % predicted: absolute change from baseline · adults and children with cystic fibrosis
2 findings from 1 review
Quality of life: change in CFQoL score from baseline · adults and children with cystic fibrosis
1 finding from 1 review
Change in BMI · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to next exacerbation · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · adults and children with cystic fibrosis
1 finding from 1 review
Global state: improvement, short term PANSS · patients with schizophrenia
Adjunctive antioxidants for schizophrenia showed no clear difference in global state: improvement, short term PANSS compared with placebo (low certainty).
1 finding from 1 review
Mental state: General ‐ average total score (PANSS, high = poor) ‐ up to 12 weeks (short‐term) · patients with schizophrenia
1 finding from 1 review
Mental state · patients with schizophrenia
1 finding from 1 review
General functioning ‐ short term GAS · patients with schizophrenia
1 finding from 1 review
General functioning ‐ medium term GAS · patients with schizophrenia
1 finding from 1 review
Behaviour: Leaving the study early (short‐term) · patients with schizophrenia
Adjunctive antioxidants for schizophrenia showed no clear difference in leaving the study early, short term compared with placebo (moderate certainty).
1 finding from 1 review
Adverse effects: 1. Serious (any time point) ‐ any serious adverse effect Various methods · patients with schizophrenia
Adjunctive antioxidants for schizophrenia showed no clear difference in adverse effects: 1. Serious (any time point) ‐ any serious adverse… compared with placebo (low certainty).
1 finding from 1 review
Length of hospital stay · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
The review found no eligible studies for this question.
1 finding from 1 review
Participant-reported resumption of normal eating, chewing and speech · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
The review found no eligible studies for this question.
1 finding from 1 review
Adverse effects · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
1 finding from 1 review
Intolerance to spicy food (participant-reported proxy) · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
Antioxidants (lycopene, curcumin, Oxitard) led to lower intolerance to spicy food (participant-reported proxy) compared with placebo or no active treatment; GRADE not reported.
1 finding from 1 review
Burning sensation (VAS 0-100) · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
Antioxidants (lycopene, curcumin, Oxitard) probably leads to lower burning sensation (VAS 0-100) compared with placebo or no active treatment (moderate certainty).
3 findings from 1 review
MD -70.82 [-94.39, -47.25]
2 studies · 500 participants
Moderate
MD -30.92 [-31.57, -30.27]
1 study · 400 participants
Moderate
MD -27.60 [-36.21, -18.99]
1 study · 90 participants
Moderate
Maximal mouth opening (interincisal distance) · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
Antioxidants (lycopene, curcumin, Oxitard) showed no clear difference in maximal mouth opening (interincisal distance) compared with placebo or no active treatment (low certainty).
3 findings from 1 review
MD -1.41 [-5.74, 2.92]
1 study · 90 participants
Low
MD 3.11 [0.46, 5.77]
2 studies · 520 participants
Low
MD 8.83 [8.22, 9.45]
3 studies · 620 participants
Moderate
Discomfort/pain · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
The review found no eligible studies for this question.
1 finding from 1 review
Difficulty in speech (participant-reported proxy) · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
Antioxidants (lycopene, curcumin, Oxitard) showed no clear difference in difficulty in speech (participant-reported proxy) compared with placebo or no active treatment; GRADE not reported.
1 finding from 1 review